104 related articles for article (PubMed ID: 15898349)
1. MK-431 (Merck).
Deacon CF
Curr Opin Investig Drugs; 2005 Apr; 6(4):419-26. PubMed ID: 15898349
[TBL] [Abstract][Full Text] [Related]
2. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
Musch A; Heinzl S
Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
[No Abstract] [Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Herman GA; Stein PP; Thornberry NA; Wagner JA
Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
[TBL] [Abstract][Full Text] [Related]
4. [Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Heinzl S
Med Monatsschr Pharm; 2006 Mar; 29(3):93-6. PubMed ID: 16550882
[No Abstract] [Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
Ahrén B
Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
[No Abstract] [Full Text] [Related]
6. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
Barnett A
Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
[TBL] [Abstract][Full Text] [Related]
7. New treatments for diabetes.
Irony I; Parks MH; Meyer RJ
N Engl J Med; 2007 May; 356(21):2221; author reply 2222-3. PubMed ID: 17526095
[No Abstract] [Full Text] [Related]
8. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
9. New treatments for diabetes.
Raz I; Eldor R
N Engl J Med; 2007 May; 356(21):2222; author reply 2222-3. PubMed ID: 17526096
[No Abstract] [Full Text] [Related]
10. Sitagliptin (Januvia) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1251):1-3. PubMed ID: 17179897
[No Abstract] [Full Text] [Related]
11. (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Biftu T; Feng D; Qian X; Liang GB; Kieczykowski G; Eiermann G; He H; Leiting B; Lyons K; Petrov A; Sinha-Roy R; Zhang B; Scapin G; Patel S; Gao YD; Singh S; Wu J; Zhang X; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2007 Jan; 17(1):49-52. PubMed ID: 17055272
[TBL] [Abstract][Full Text] [Related]
12. New treatments for diabetes.
Mintz ML
N Engl J Med; 2007 May; 356(21):2221-2; author reply 2222-3. PubMed ID: 17526094
[No Abstract] [Full Text] [Related]
13. DPP-4 inhibitors. A new class of drugs for type 2 diabetes.
Marino MT
Diabetes Self Manag; 2008; 25(4):60, 62-4. PubMed ID: 18717028
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
15. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
Matthes J; Faust M
Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
[No Abstract] [Full Text] [Related]
16. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
17. A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
Donnelly R
Diabetes Obes Metab; 2007 Mar; 9(2):151-2. PubMed ID: 17300590
[No Abstract] [Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action.
Drucker DJ
Diabetes Care; 2007 Jun; 30(6):1335-43. PubMed ID: 17337495
[No Abstract] [Full Text] [Related]
19. cis-2,5-dicyanopyrrolidine inhibitors of dipeptidyl peptidase IV: synthesis and in vitro, in vivo, and X-ray crystallographic characterization.
Wright SW; Ammirati MJ; Andrews KM; Brodeur AM; Danley DE; Doran SD; Lillquist JS; McClure LD; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soeller WC; Soglia CB; Treadway JL; VanVolkenburg MA; Wang H; Wilder DC; Olson TV
J Med Chem; 2006 Jun; 49(11):3068-76. PubMed ID: 16722626
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Herman GA; Bergman A; Liu F; Stevens C; Wang AQ; Zeng W; Chen L; Snyder K; Hilliard D; Tanen M; Tanaka W; Meehan AG; Lasseter K; Dilzer S; Blum R; Wagner JA
J Clin Pharmacol; 2006 Aug; 46(8):876-86. PubMed ID: 16855072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
